Back

Novo Nordisk weighs New York listing upgrade to raise U.S. profile

Verifying
  • Novo Nordisk is considering upgrading its New York listing.
  • CEO Mike Doustdar cited advantages to a direct New York Stock Exchange listing.
  • American depositary receipts currently provide U.S. investors access to Novo’s stock.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.